I'm guided by the desire to make our world-class physician-scientists and cutting-edge technology more accessible to all families. As a neurologist and hospital leader, I believe science has practical implications and can offer real hope for improved care of patients.

MEDICAL SERVICES

EDUCATION

Medical School

  • University of Cincinnati College of Medicine , 1982 , Cincinnati , OH

Residency

Pediatrics
  • Boston Children's Hospital , 1984 , Boston , MA

Residency

Child Neurology
  • Washington University/Children’s Hospital , 1987 , St. Louis , MO

Fellowship

Child Neurology and Neurobiology
  • Washington University , 1990 , St. Louis , MO

Philosophy of Care

My approach to care reflects the Midwestern values instilled in me by my father, a nuclear engineer, and my mother, a nursery school teacher. The small-town sensibility of my Ohio upbringing taught me self sufficiency, respect for others and the importance of pulling my own weight. I am also a self-identified nerd.  I feel at home in the lab and love to spend time among researchers.

I became interested in science at a young age. My father, who was part of a post World War II project to design and build a nuclear airplane, infused my childhood with the cutting-edge ideas of the time -- atomic energy, space travel, and physics. The human side of who I would become as a doctor emerged during the Civil Rights movement, with its emphasis on the rights of others. I became interested in the potential of science to make real change, and I wanted to work on a problem that could mean real results for my patients.

My decision to treat children grew out of volunteer work at Cincinnati Children's Hospital. I worked Friday night shifts after high school and through college in the emergency room, and the work was very hands on -- I was tasked with holding children during procedures in the emergency room, working with them in the hospital child life program and visiting children at their bedsides after they were admitted to the hospital. Getting to know very ill children taught me that doctors must treat them in the context of the entire family.

A trip to the hospital can be a life changing event especially in my area of specialty, childhood brain tumors. Our approach offers hope from cutting edge science driven therapies together with care for the whole child and family, supporting them through one of the worst events of their lives. I received the first Compassionate Caregiver Award, awarded by the Kenneth Schwartz Center in 1999.

PROFESSIONAL HISTORY

Dr. Pomeroy serves as an expert for the Department of Neurology for Boston Children's Hospital Precision Medicine Service. For more information about the Precision Medicine Service please visit bostonchildrens.org/precisionmed.

I'm guided by the desire to make our world-class physician-scientists and cutting-edge technology more accessible to all families. As a neurologist and hospital leader, I believe science has practical implications and can offer real hope for improved care of patients.

My commitment to both research and medicine was reflected in my decision to pursue both an M.D. and PhD. at the University of Cincinnati. I then trained in pediatrics at Boston Children's Hospital and child neurology at Washington University in St. Louis. Early on in my career, I longed to find a problem for which basic science would have a major impact on improving care and chose to focus on childhood brain tumors. 

I have focused primarily on the treatment of children with medulloblastomas -- the most common malignant brain tumors in kids.  Given their malignant behavior, treatment of these tumors is extremely aggressive, involving a protracted course of chemotherapy and radiation to the entire brain.  Survivors are left with life-altering cognitive deficits.

The advent of technology that could rapidly monitor the activity of all genes throughout the human genome gave me the opportunity to study the tumor samples in depth. Thus, clinical practice informed a research breakthrough: we discovered that the molecular profiles of tumors predict the treatment response of medulloblastomas much more accurately than clinical criteria that were in use at the time. This finding allowed us to classify brain tumors by their molecular features, better predicting outcomes for patients and allowing us to increase treatment of poor outcome tumors while decreasing treatment of tumors that respond to therapy in order to improve the cognitive outcome of survivors.  We also are able to introduce therapies that target molecular mechanisms, enabling further reduction or even elimination of less specific and damaging chemotherapy and radiation. These research and clinical experiences led, in 2010, to my appointment as the Director of the Boston Children’s Hospital / Harvard Medical School Intellectual and Developmental Disabilities Research Center.

In the clinical arena, I worked toward the establishment of our multidisciplinary Brain Tumor Center in 1992 and helped to grow it to one of the largest such programs nationwide. After becoming Boston Children's Hospital's Neurologist-in-Chief in 2005, I have dedicated my efforts toward better coordinating care for our patients, many of whom have complex needs. Under my direction, families now come into integrated systems for autism, learning disabilities and many other disorders of the brain. I have also been instrumental in advocating for the establishment of the hospital's shared service center. This has streamlined registration and billing, making Boston Children's Hospital a more nimble, patient-centered organization. I am proud to have made the experience of coming to the hospital an easier one for families of children with complex needs.

CERTIFICATIONS

  • American Board of Psychiatry and Neurology, Child and Adolescent Neurology

PUBLICATIONS

Publications powered by Harvard Catalyst Profiles

  1. Children's Oncology Group Phase III Trial of Reduced-Dose and Reduced-Volume Radiotherapy With Chemotherapy for Newly Diagnosed Average-Risk Medulloblastoma. J Clin Oncol. 2021 Aug 20; 39(24):2685-2697. View abstract
  2. TORC1/2 kinase inhibition depletes glutathione and synergizes with carboplatin to suppress the growth of MYC-driven medulloblastoma. Cancer Lett. 2021 04 28; 504:137-145. View abstract
  3. Loss of Consciousness in the Young Child. Pediatr Cardiol. 2021 Feb; 42(2):234-254. View abstract
  4. Crisis Standard of Care: Management of Infantile Spasms during COVID-19. Ann Neurol. 2020 08; 88(2):215-217. View abstract
  5. Epigenetics and survivorship in pediatric brain tumor patients. J Neurooncol. 2020 Oct; 150(1):77-83. View abstract
  6. Pineoblastoma segregates into molecular sub-groups with distinct clinico-pathologic features: a Rare Brain Tumor Consortium registry study. Acta Neuropathol. 2020 02; 139(2):223-241. View abstract
  7. Single-Cell Transcriptomics in Medulloblastoma Reveals Tumor-Initiating Progenitors and Oncogenic Cascades during Tumorigenesis and Relapse. Cancer Cell. 2019 09 16; 36(3):302-318.e7. View abstract
  8. Intellectual and developmental disabilities research centers: Fifty years of scientific accomplishments. Ann Neurol. 2019 09; 86(3):332-343. View abstract
  9. Resolving medulloblastoma cellular architecture by single-cell genomics. Nature. 2019 08; 572(7767):74-79. View abstract
  10. Medulloblastoma. Nat Rev Dis Primers. 2019 02 14; 5(1):11. View abstract
  11. Proteomics, Post-translational Modifications, and Integrative Analyses Reveal Molecular Heterogeneity within Medulloblastoma Subgroups. Cancer Cell. 2018 09 10; 34(3):396-410.e8. View abstract
  12. Rapid discrimination of pediatric brain tumors by mass spectrometry imaging. J Neurooncol. 2018 Nov; 140(2):269-279. View abstract
  13. Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. Lancet Oncol. 2018 06; 19(6):785-798. View abstract
  14. Brain cancer genomics and epigenomics. Handb Clin Neurol. 2018; 148:785-797. View abstract
  15. The whole-genome landscape of medulloblastoma subtypes. Nature. 2017 07 19; 547(7663):311-317. View abstract
  16. MicroRNA-1301 suppresses tumor cell migration and invasion by targeting the p53/UBE4B pathway in multiple human cancer cells. Cancer Lett. 2017 08 10; 401:20-32. View abstract
  17. The evolution of medulloblastoma therapy to personalized medicine. F1000Res. 2017; 6:490. View abstract
  18. Medulloblastoma: Molecular Classification-Based Personal Therapeutics. Neurotherapeutics. 2017 04; 14(2):265-273. View abstract
  19. OTX2 Activity at Distal Regulatory Elements Shapes the Chromatin Landscape of Group 3 Medulloblastoma. Cancer Discov. 2017 03; 7(3):288-301. View abstract
  20. Tracking the Fate of Cells in Health and Disease. N Engl J Med. 2016 Dec 22; 375(25):2494-2496. View abstract
  21. SMARCB1-mediated SWI/SNF complex function is essential for enhancer regulation. Nat Genet. 2017 Feb; 49(2):289-295. View abstract
  22. The Evolution of Child Neurology Training. Pediatr Neurol. 2017 01; 66:3-4. View abstract
  23. First In Vivo Testing of Compounds Targeting Group 3 Medulloblastomas Using an Implantable Microdevice as a New Paradigm for Drug Development. J Biomed Nanotechnol. 2016 Jun; 12(6):1297-302. View abstract
  24. Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. Acta Neuropathol. 2016 06; 131(6):821-31. View abstract
  25. DiSCoVERing Innovative Therapies for Rare Tumors: Combining Genetically Accurate Disease Models with In Silico Analysis to Identify Novel Therapeutic Targets. Clin Cancer Res. 2016 08 01; 22(15):3903-14. View abstract
  26. A clinic devoted to peer victimization in special needs children. Ann Neurol. 2016 Feb; 79(2):167-8. View abstract
  27. Incidence, risk factors, and longitudinal outcome of seizures in long-term survivors of pediatric brain tumors. Epilepsia. 2015 Oct; 56(10):1599-604. View abstract
  28. Defining the molecular landscape of ependymomas. Cancer Cell. 2015 May 11; 27(5):613-5. View abstract
  29. WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma. Acta Neuropathol Commun. 2014 Dec 24; 2:174. View abstract
  30. The G protein a subunit Gas is a tumor suppressor in Sonic hedgehog-driven medulloblastoma. Nat Med. 2014 Sep; 20(9):1035-42. View abstract
  31. Modelling high myc medulloblastoma and other brain tumors using human neural stem cells. Neuro Oncol. 2014 Jul; 16 Suppl 3:iii4. View abstract
  32. Could a5-GABA-A receptor activation be used as a target for managing medulloblastomas? CNS Oncol. 2014 Jul; 3(4):245-7. View abstract
  33. CNS-PNETs with C19MC amplification and/or LIN28 expression comprise a distinct histogenetic diagnostic and therapeutic entity. Acta Neuropathol. 2014 Aug; 128(2):291-303. View abstract
  34. Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. Cancer Cell. 2014 Mar 17; 25(3):393-405. View abstract
  35. Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. Nature. 2014 Feb 27; 506(7489):445-50. View abstract
  36. Cytogenetic prognostication within medulloblastoma subgroups. J Clin Oncol. 2014 Mar 20; 32(9):886-96. View abstract
  37. A developmental program drives aggressive embryonal brain tumors. Nat Genet. 2014 Jan; 46(1):2-3. View abstract
  38. Medulloblastoma Down Under 2013: a report from the third annual meeting of the International Medulloblastoma Working Group. Acta Neuropathol. 2014 Feb; 127(2):189-201. View abstract
  39. a5-GABAA receptors negatively regulate MYC-amplified medulloblastoma growth. Acta Neuropathol. 2014 Apr; 127(4):593-603. View abstract
  40. Inactivation of the tumor suppressor WTX in a subset of pediatric tumors. Genes Chromosomes Cancer. 2014 Jan; 53(1):67-77. View abstract
  41. TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathol. 2013 Dec; 126(6):917-29. View abstract
  42. Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. Lancet Oncol. 2013 Nov; 14(12):1200-7. View abstract
  43. Message from the incoming editor. Ann Neurol. 2013 Sep; 74(3):A9-A10. View abstract
  44. Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. J Clin Oncol. 2013 Aug 10; 31(23):2927-35. View abstract
  45. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet. 2013 Aug; 45(8):927-32. View abstract
  46. Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1. Proc Natl Acad Sci U S A. 2013 May 14; 110(20):8188-93. View abstract
  47. Clinical practice guidelines and practice parameters for the child neurologist. J Child Neurol. 2013 Jul; 28(7):917-25. View abstract
  48. Activation of ß-catenin/TCF targets following loss of the tumor suppressor SNF5. Oncogene. 2014 Feb 13; 33(7):933-8. View abstract
  49. A novel syndrome caused by the E410K amino acid substitution in the neuronal ß-tubulin isotype 3. Brain. 2013 Feb; 136(Pt 2):522-35. View abstract
  50. Medulloblastomics: the end of the beginning. Nat Rev Cancer. 2012 Dec; 12(12):818-34. View abstract
  51. Medulloblastoma biology in the post-genomic era. Future Oncol. 2012 Dec; 8(12):1597-604. View abstract
  52. Sport-related concussion: time to take notice. Curr Opin Pediatr. 2012 Dec; 24(6):687-8. View abstract
  53. Dissecting the genomic complexity underlying medulloblastoma. Nature. 2012 Aug 02; 488(7409):100-5. View abstract
  54. Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature. 2012 Aug 02; 488(7409):49-56. View abstract
  55. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature. 2012 Aug 02; 488(7409):106-10. View abstract
  56. Markers of survival and metastatic potential in childhood CNS primitive neuro-ectodermal brain tumours: an integrative genomic analysis. Lancet Oncol. 2012 Aug; 13(8):838-48. View abstract
  57. Epigenetic inactivation of the tumor suppressor BIN1 drives proliferation of SNF5-deficient tumors. . 2012 May 15; 11(10):1956-65. View abstract
  58. Sleep dysfunction in long term survivors of craniopharyngioma. J Neurooncol. 2012 Jul; 108(3):543-9. View abstract
  59. Hedgehog-GLI pathway in medulloblastoma. J Clin Oncol. 2012 Jun 10; 30(17):2154-6. View abstract
  60. Pleiotropic effects of miR-183~96~182 converge to regulate cell survival, proliferation and migration in medulloblastoma. Acta Neuropathol. 2012 Apr; 123(4):539-52. View abstract
  61. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol. 2012 Apr; 123(4):473-84. View abstract
  62. MicroRNA-182 promotes leptomeningeal spread of non-sonic hedgehog-medulloblastoma. Acta Neuropathol. 2012 Apr; 123(4):529-38. View abstract
  63. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol. 2012 Apr; 123(4):465-72. View abstract
  64. Recent advances in autism spectrum disorders. Curr Opin Pediatr. 2011 Dec; 23(6):607-8. View abstract
  65. Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples. Acta Neuropathol. 2012 Apr; 123(4):615-26. View abstract
  66. Posterior fossa ependymomas: a tale of two subtypes. Cancer Cell. 2011 Aug 16; 20(2):133-4. View abstract
  67. Neuro-oncology training for the child neurology resident. Semin Pediatr Neurol. 2011 Jun; 18(2):120-2. View abstract
  68. Training the next generation of child neurologists - a neuroscience based approach. Ann Neurol. 2011 Jun; 69(6):A9-A10. View abstract
  69. Molecular fingerprints of medulloblastoma and their application to clinical practice. Future Oncol. 2011 Mar; 7(3):327-9. View abstract
  70. Predicting relapse in patients with medulloblastoma by integrating evidence from clinical and genomic features. J Clin Oncol. 2011 Apr 10; 29(11):1415-23. View abstract
  71. UBE4B promotes Hdm2-mediated degradation of the tumor suppressor p53. Nat Med. 2011 Mar; 17(3):347-55. View abstract
  72. Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences. Nat Commun. 2011 Feb 01; 2:180. View abstract
  73. miR-34a confers chemosensitivity through modulation of MAGE-A and p53 in medulloblastoma. Neuro Oncol. 2011 Feb; 13(2):165-75. View abstract
  74. Growing spectrum and relevance of pediatric neuro-immunology. Curr Opin Pediatr. 2010 Dec; 22(6):717. View abstract
  75. Long-term clinical outcomes following treatment of childhood craniopharyngioma. Pediatr Blood Cancer. 2011 Jul 01; 56(7):1120-6. View abstract
  76. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol. 2011 Apr 10; 29(11):1424-30. View abstract
  77. Loss of the tumor suppressor Snf5 leads to aberrant activation of the Hedgehog-Gli pathway. Nat Med. 2010 Dec; 16(12):1429-33. View abstract
  78. Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation. Cancer Cell. 2010 Oct 19; 18(4):316-28. View abstract
  79. Neuralized1 causes apoptosis and downregulates Notch target genes in medulloblastoma. Neuro Oncol. 2010 Dec; 12(12):1244-56. View abstract
  80. The landscape of somatic copy-number alteration across human cancers. Nature. 2010 Feb 18; 463(7283):899-905. View abstract
  81. Human TUBB3 mutations perturb microtubule dynamics, kinesin interactions, and axon guidance. Cell. 2010 Jan 08; 140(1):74-87. View abstract
  82. Frequent amplification of a chr19q13.41 microRNA polycistron in aggressive primitive neuroectodermal brain tumors. Cancer Cell. 2009 Dec 08; 16(6):533-46. View abstract
  83. Pathologic intracellular signaling in childhood pilocytic astrocytomas. Neurology. 2009 Nov 10; 73(19):1522-3. View abstract
  84. Melatonin deficiency and disrupted circadian rhythms in pediatric survivors of craniopharyngioma. Neurology. 2009 Jul 28; 73(4):323-5. View abstract
  85. Pediatric sleep medicine in 2008: state-of-the-art. Curr Opin Pediatr. 2008 Dec; 20(6):639-40. View abstract
  86. Loss of the epigenetic tumor suppressor SNF5 leads to cancer without genomic instability. Mol Cell Biol. 2008 Oct; 28(20):6223-33. View abstract
  87. Cardiac risk after craniopharyngioma therapy. Pediatr Neurol. 2008 Apr; 38(4):256-60. View abstract
  88. The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. Genes Dev. 2008 Apr 01; 22(7):884-93. View abstract
  89. Schwann cell proliferation during Wallerian degeneration is not necessary for regeneration and remyelination of the peripheral nerves: axon-dependent removal of newly generated Schwann cells by apoptosis. Mol Cell Neurosci. 2008 May; 38(1):80-8. View abstract
  90. Introduction: survivors of childhood cancer: the new face of developmental disabilities. Dev Disabil Res Rev. 2008; 14(3):183-4. View abstract
  91. Gain of 1q is a potential univariate negative prognostic marker for survival in medulloblastoma. Clin Cancer Res. 2007 Dec 01; 13(23):7022-8. View abstract
  92. Moyamoya following cranial irradiation for primary brain tumors in children. Neurology. 2007 Mar 20; 68(12):932-8. View abstract
  93. Overlay analysis of the oligonucleotide array gene expression profiles and copy number abnormalities as determined by array comparative genomic hybridization in medulloblastomas. Genes Chromosomes Cancer. 2007 Jan; 46(1):53-66. View abstract
  94. Molecular genetics of pediatric central nervous system tumors. Curr Oncol Rep. 2006 Nov; 8(6):423-9. View abstract
  95. Medulloblastoma outcome is adversely associated with overexpression of EEF1D, RPL30, and RPS20 on the long arm of chromosome 8. BMC Cancer. 2006 Sep 12; 6:223. View abstract
  96. Transverse myelitis after therapy for primitive neuroectodermal tumors. Pediatr Neurol. 2006 Aug; 35(2):122-5. View abstract
  97. Medulloblastoma Subtypes Defined by Gene Expression Analysis 864. Neurosurgery. 2006 Aug 01; 59(2):475. View abstract
  98. Everyday cognitive function after craniopharyngioma in childhood. Pediatr Neurol. 2006 Jan; 34(1):13-9. View abstract
  99. Inactivation of the Snf5 tumor suppressor stimulates cell cycle progression and cooperates with p53 loss in oncogenic transformation. Proc Natl Acad Sci U S A. 2005 Dec 06; 102(49):17745-50. View abstract
  100. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005 Oct 25; 102(43):15545-50. View abstract
  101. Ataxia and shaking in a 2-year-old girl: acute marijuana intoxication presenting as seizure. Pediatr Emerg Care. 2005 Aug; 21(8):527-8. View abstract
  102. A novel role for extracellular signal-regulated kinase 5 and myocyte enhancer factor 2 in medulloblastoma cell death. Cancer Res. 2005 Jul 01; 65(13):5683-9. View abstract
  103. Diencephalic syndrome: a cause of failure to thrive and a model of partial growth hormone resistance. Pediatrics. 2005 Jun; 115(6):e742-8. View abstract
  104. INI1 protein expression distinguishes atypical teratoid/rhabdoid tumor from choroid plexus carcinoma. J Neuropathol Exp Neurol. 2005 May; 64(5):391-7. View abstract
  105. Continuous remission of newly diagnosed and relapsed central nervous system atypical teratoid/rhabdoid tumor. J Neurooncol. 2005 Mar; 72(1):77-84. View abstract
  106. Stereotactic radiotherapy for localized low-grade gliomas in children: final results of a prospective trial. Int J Radiat Oncol Biol Phys. 2005 Feb 01; 61(2):374-9. View abstract
  107. Craniopharyngioma therapy: long-term effects on hypothalamic function. Neurologist. 2005 Jan; 11(1):55-60. View abstract
  108. Intracerebral abscess in children: historical trends at Children's Hospital Boston. Pediatrics. 2004 Jun; 113(6):1765-70. View abstract
  109. Neural development and the ontogeny of central nervous system tumors. Neuron Glia Biol. 2004 May; 1(2):127-33. View abstract
  110. Conserved mechanisms across development and tumorigenesis revealed by a mouse development perspective of human cancers. Genes Dev. 2004 Mar 15; 18(6):629-40. View abstract
  111. Combining gene expression profiles and clinical parameters for risk stratification in medulloblastomas. J Clin Oncol. 2004 Mar 15; 22(6):994-8. View abstract
  112. Molecular biology of medulloblastoma therapy. Pediatr Neurosurg. 2003 Dec; 39(6):299-304. View abstract
  113. Medulloblastoma tumorigenesis diverges from cerebellar granule cell differentiation in patched heterozygous mice. Dev Biol. 2003 Nov 01; 263(1):50-66. View abstract
  114. Pediatric brain tumors. Neurol Clin. 2003 Nov; 21(4):897-913. View abstract
  115. Progressive myoclonus in a child with a deep cerebellar mass. Neurology. 2003 Sep 23; 61(6):829-31. View abstract
  116. Marked regression of metastatic pilocytic astrocytoma during treatment with imatinib mesylate (STI-571, Gleevec): a case report and laboratory investigation. J Pediatr Hematol Oncol. 2003 Aug; 25(8):644-8. View abstract
  117. Neuropsychological functioning after surgery in children treated for brain tumor. Neurosurgery. 2003 Jun; 52(6):1348-56; discussion 1356-7. View abstract
  118. Application of microarrays to neurological disease. Arch Neurol. 2003 May; 60(5):676-82. View abstract
  119. Magnetic resonance imaging of patched heterozygous and xenografted mouse brain tumors. J Neurooncol. 2003 May; 62(3):259-67. View abstract
  120. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res. 2003 Apr 01; 63(7):1602-7. View abstract
  121. A phase I trial of etanidazole and hyperfractionated radiotherapy in children with diffuse brainstem glioma. Int J Radiat Oncol Biol Phys. 2003 Apr 01; 55(5):1182-5. View abstract
  122. Medulloblastomas and primitive neuroectodermal tumors rarely contain polyomavirus DNA sequences. Neuro Oncol. 2002 07; 4(3):165-70. View abstract
  123. High-resolution imaging demonstrates dynein-based vesicular transport of activated Trk receptors. J Neurobiol. 2002 Jun 15; 51(4):302-12. View abstract
  124. Focus on central nervous system neoplasia. Cancer Cell. 2002 Mar; 1(2):125-8. View abstract
  125. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature. 2002 Jan 24; 415(6870):436-42. View abstract
  126. Memory deficits among children with craniopharyngiomas. Neurosurgery. 2001 Nov; 49(5):1053-7; discussion 1057-8. View abstract
  127. Psychometric testing in bacterial meningitis: results of a long-term prospective study of infants and children treated between 1973 and 1977. J Child Neurol. 2001 Nov; 16(11):854-7. View abstract
  128. Children with headache suspected of having a brain tumor: a cost-effectiveness analysis of diagnostic strategies. Pediatrics. 2001 Aug; 108(2):255-63. View abstract
  129. Analysis of the SDHD gene, the susceptibility gene for familial paraganglioma syndrome (PGL1), in pheochromocytomas. J Clin Endocrinol Metab. 2001 Jun; 86(6):2890-4. View abstract
  130. Circulating serpin tumor markers SCCA1 and SCCA2 are not actively secreted but reside in the cytosol of squamous carcinoma cells. Int J Cancer. 2000 Jul 20; 89(4):368-77. View abstract
  131. Identification of PATCHED mutations in medulloblastomas by direct sequencing. Hum Mutat. 2000 Jul; 16(1):89-90. View abstract
  132. Neurological dysfunction associated with postoperative cerebellar mutism. J Neurooncol. 2000 May; 48(1):75-81. View abstract
  133. A developmentally regulated switch directs regenerative growth of Schwann cells through cyclin D1. Neuron. 2000 May; 26(2):405-16. View abstract
  134. Biology and pathobiology of neuronal development. Ment Retard Dev Disabil Res Rev. 2000; 6(1):41-6. View abstract
  135. Rapid nuclear responses to target-derived neurotrophins require retrograde transport of ligand-receptor complex. J Neurosci. 1999 Sep 15; 19(18):7889-900. View abstract
  136. Basal ganglia germinoma with progressive cerebral hemiatrophy. Pediatr Neurol. 1999 Apr; 20(4):312-4. View abstract
  137. Isoflavones from red clover improve systemic arterial compliance but not plasma lipids in menopausal women. J Clin Endocrinol Metab. 1999 Mar; 84(3):895-8. View abstract
  138. Activation of neurotrophin-3 receptor TrkC induces apoptosis in medulloblastomas. Cancer Res. 1999 Feb 01; 59(3):711-9. View abstract
  139. Human immunodeficiency virus type 1 long terminal repeat quasispecies differ in basal transcription and nuclear factor recruitment in human glial cells and lymphocytes. J Biomed Sci. 1998; 5(1):31-44. View abstract
  140. Neurotrophins in cerebellar granule cell development and medulloblastoma. J Neurooncol. 1997 Dec; 35(3):347-52. View abstract
  141. Activation of ErbB2 during wallerian degeneration of sciatic nerve. J Neurosci. 1997 Nov 01; 17(21):8293-9. View abstract
  142. Trk receptors function as rapid retrograde signal carriers in the adult nervous system. J Neurosci. 1997 Sep 15; 17(18):7007-16. View abstract
  143. Abnormal cerebellar development and foliation in BDNF-/- mice reveals a role for neurotrophins in CNS patterning. Neuron. 1997 Aug; 19(2):269-81. View abstract
  144. Postnatal addition of satellite cells to parasympathetic neurons. J Comp Neurol. 1996 Nov 18; 375(3):518-25. View abstract
  145. Magnetic resonance imaging changes after stereotactic radiation therapy for childhood low grade astrocytoma. Cancer. 1996 Aug 15; 78(4):864-73. View abstract
  146. Axonal growth and fasciculation linked to differential expression of BDNF and NT3 receptors in developing cerebellar granule cells. J Neurosci. 1995 Jul; 15(7 Pt 1):4970-81. View abstract
  147. Neurobehavioral and neurologic outcome in long-term survivors of posterior fossa brain tumors: role of age and perioperative factors. J Child Neurol. 1995 May; 10(3):209-12. View abstract
  148. Hemorrhagic vasculopathy after treatment of central nervous system neoplasia in childhood: diagnosis and follow-up. AJNR Am J Neuroradiol. 1995 Apr; 16(4):693-9. View abstract
  149. Expression of the neurotrophin receptor TrkC is linked to a favorable outcome in medulloblastoma. Proc Natl Acad Sci U S A. 1994 Dec 20; 91(26):12867-71. View abstract
  150. The p53 tumor suppressor gene and pediatric brain tumors. Curr Opin Pediatr. 1994 Dec; 6(6):632-5. View abstract
  151. Stereotactic radiotherapy for pediatric and adult brain tumors: preliminary report. Int J Radiat Oncol Biol Phys. 1994 Oct 15; 30(3):531-9. View abstract
  152. Advances in radiation therapy for craniopharyngiomas. Pediatr Neurosurg. 1994; 21 Suppl 1:101-7. View abstract
  153. Vital imaging of glomeruli in the mouse olfactory bulb. J Neurosci. 1992 Mar; 12(3):976-88. View abstract
  154. Seizures and other neurologic sequelae of bacterial meningitis in children. N Engl J Med. 1990 Dec 13; 323(24):1651-7. View abstract
  155. Postnatal construction of neural circuitry in the mouse olfactory bulb. J Neurosci. 1990 Jun; 10(6):1952-66. View abstract
  156. Neuron/glia relationships observed over intervals of several months in living mice. J Cell Biol. 1988 Sep; 107(3):1167-75. View abstract
  157. Effect of morphine injectedin periadueductal gray on the activity of single units in nucleus raphe magnus of the rat. Brain Res. 1978 Jun 23; 149(1):266-9. View abstract